Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Furthermore, Novo Nordisk derives a substantial portion of its revenue from its GLP-1 products; in 2024, Ozempic and Wegovy made up 61.5% of Novo Nordisk's total sales. But the company also has a ...

A study explored if semaglutide – sold under the brand names Wegovy, Ozempic ... Novo Nordisk misreported 65 payments. The PMCPA said Novo Nordisk accepted breaches of clauses 24.1, 24.4 ...

The probe alleged 30 organisations were missed from the company’s disclosures and claims Novo Nordisk misreported 65 payments. The PMCPA said Novo Nordisk accepted breaches of clauses 24.1 ...